avonex
biogen nz biopharma ltd - interferon beta-1a 30ug; - injection with diluent - 30 mcg - active: interferon beta-1a 30ug excipient: albumin dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).
avonex
biogen nz biopharma ltd - interferon beta-1a 60 µg/ml - solution for injection - 30 mcg/0.5ml - active: interferon beta-1a 60 µg/ml excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).
avonex pen
biogen nz biopharma ltd - interferon beta-1a 60 µg/ml - solution for injection - 30 mcg/0.5ml - active: interferon beta-1a 60 µg/ml excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).
rebif
merck europe b.v. - interferon beta-1a - multiple sclerosis - immunostimulants, - rebif is indicated for the treatment of:patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing multiple sclerosis. in clinical trials, this was characterised by two or more acute exacerbations in the previous two years.efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity.
avonex
biogen netherlands b.v. - interferon beta-1a - multiple sclerosis - immunostimulants, - avonex is indicated for the treatment of:patients diagnosed with relapsing multiple sclerosis (ms). in clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; avonex slows the progression of disability and decreases the frequency of relapses;patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite ms.avonex should be discontinued in patients who develop progressive ms.
betaferon
bayer ag - interferon beta-1b - multiple sclerosis - immunostimulants, - betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
plegridy liquid
biogen canada inc - peginterferon beta-1a - liquid - 63mcg - peginterferon beta-1a 63mcg - interferons
plegridy liquid
biogen canada inc - peginterferon beta-1a - liquid - 94mcg - peginterferon beta-1a 94mcg - interferons
plegridy liquid
biogen canada inc - peginterferon beta-1a - liquid - 125mcg - peginterferon beta-1a 125mcg - interferons
avonex powder for solution
biogen canada inc - interferon beta-1a; water - powder for solution - 30mcg; 1.1ml - interferon beta-1a 30mcg; water 1.1ml - immunomodulatory agents